Publicaties
Gekozen filters:
Gekozen filters:
MDM2 in Soft Tissue and Bone Sarcomas KU Leuven
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial KU Leuven
Recent phase II and III clinical trials demonstrated anti-tumour activity of eribulin, a tubulin-interacting cytotoxic agent, in patients with metastatic soft tissue sarcoma (STS). In this exploratory study, we aimed to identify putative microRNA biomarkers that associate with eribulin sensitivity or resistance in STS.
MDM2 expression in extranodal abdominal and retroperitoneal follicular dendritic cell sarcomas mimicking dedifferentiated liposarcomas Universiteit Gent
Feasibility of tomotherapy for postoperative irradiation of lower extremity sarcomas Vrije Universiteit Brussel
Conclusion. IGRT delivered by tomotherapy may be ideally suited for sarcoma of the extremities because of its ability to achieve a high radiation dose along with excellent normal tissue sparing. Further prospective studies should be conducted to confirm this hypothesis.
Aims and background. To evaluate the effectiveness of helical tomotherapy-based image-guided radiotherapy (IGRT) following surgery for lower extremity ...
Primary renal sarcomas : imaging features and discrimination from non-sarcoma renal tumors Universiteit Gent
Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin KU Leuven
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Soft-tissue sarcomas (STS) are a diverse group of rare mesenchymal malignancies. Treatment options for advanced STS following failure of first-line chemotherapy remain limited. Areas covered: Summary of established second- or later-line regimens for advanced STS and a discussion of clinical evidence in support of eribulin use, focused on the treatment of liposarcomas ...